drugset
drugset / Trial / NCT01912404

Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy

NCT01912404 ↗

Phase 2 Terminated 5 enrolled Conatus Pharmaceuticals Inc. National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main purpose of the study is to test if taking a study drug called emricasan (also known as IDN-6556 and PF-03491390) will affect overall patient survival after one month of treatment.

Timeline

Start
2013-07
Primary completion
2015-08
Completion
2015-08

Outcome

Outcome not reported

Stopped: “Due to concern for high systemic drug levels that could exceed levels in toxicology studies.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Emricasan Small molecule 25 mg —

Indications

alcoholic hepatitis